|
1
|
Brosseau S, Viala M, Varga A, Planchard D,
Besse B and Soria JC: 3rd generation's TKI in lung cancer non-small
cell EGFR-mutated having acquired a secondary T790M resistance.
Bull Cancer. 102:749–757. 2015.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ymer SI, Greenall SA, Cvrljevic A, Cao DX,
Donoghue JF, Epa VC, Scott AM, Adams TE and Johns TG: Glioma
specific extracellular missense mutations in the first cysteine
rich region of epidermal growth factor receptor (EGFR) initiate
ligand independent activation. cancers (Basel). 3:2032–2049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li N, Lorinczi M, Ireton K and Elferink
LA: Specific Grb2-mediated interactions regulate clathrin-dependent
endocytosis of the cMet-tyrosine kinase. J Biol Chem.
282:16764–16775. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shinomiya N, Gao CF, Xie Q, Gustafson M,
Waters DJ, Zhang YW and Woude GF Vande: RNA interference reveals
that ligand-independent met activity is required for tumor cell
signaling and survival. Cancer Res. 64:7962–7970. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pillay V, Allaf L, Wilding AL, Donoghue
JF, Court NW, Greenall SA, Scott AM and Johns TG: The plasticity of
oncogene addiction: implications for targeted therapies directed to
receptor tyrosine kinases. Neoplasia. 11:448–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frederick L, Eley G, Wang XY and James CD:
Analysis of genomic rearrangements associated with EGRFvIII
expression suggests involvement of Alu repeat elements. Neuro
Oncol. 2:159–163. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bertotti A, Burbridge MF, Gastaldi S,
Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes
G, Lockhart BP, et al: Only a subset of Met-activated pathways are
required to sustain oncogene addiction. Sci Signal. 2:ra80. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al TCGA Research Network, : The somatic genomic
landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Verhaak RGW, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al
Cancer genome atlas research network, : Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohgaki H and Kleihues P: Genetic
alterations and signaling pathways in the evolution of gliomas.
Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wong AJ, Ruppert JM, Bigner SH, Grzeschik
CH, Humphrey PA, Bigner DS and Vogelstein B: Structural alterations
of the epidermal growth factor receptor gene in human gliomas. Proc
Natl Acad Sci USA. 89:pp. 2965–2969. 1992; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shinojima N, Tada K, Shiraishi S, Kamiryo
T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et
al: Prognostic value of epidermal growth factor receptor in
patients with glioblastoma multiforme. Cancer Res. 63:6962–6970.
2003.PubMed/NCBI
|
|
14
|
Hwang Y, Chumbalkar V, Latha K and Bogler
O: Forced dimerization increases the activity of ΔEGFR/EGFRvIII and
enhances its oncogenicity. Mol Cancer Res. 9:1199–1208. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmidt MHH, Furnari FB, Cavenee WK and
Bögler O: Epidermal growth factor receptor signaling intensity
determines intracellular protein interactions, ubiquitination, and
internalization. Proc Natl Acad Sci USA. 100:pp. 6505–6510. 2003;
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagane M, Coufal F, Lin H, Bögler O,
Cavenee WK and Huang HJ: A common mutant epidermal growth factor
receptor confers enhanced tumorigenicity on human glioblastoma
cells by increasing proliferation and reducing apoptosis. Cancer
Res. 56:5079–5086. 1996.PubMed/NCBI
|
|
17
|
Bachoo RM, Maher EA, Ligon KL, Sharpless
NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R,
et al: Epidermal growth factor receptor and Ink4a/Arf: Convergent
mechanisms governing terminal differentiation and transformation
along the neural stem cell to astrocyte axis. Cancer Cell.
1:269–277. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishikawa R, Ji XD, Harmon RC, Lazar CS,
Gill GN, Cavenee WK and Huang HJ: A mutant epidermal growth factor
receptor common in human glioma confers enhanced tumorigenicity.
Proc Natl Acad Sci USA. 91:pp. 7727–7731. 1994; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cavenee WK: Genetics and new approaches to
cancer therapy. Carcinogenesis. 23:683–686. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lammering G, Valerie K, Lin PS, Hewit TH
and Schmidt-Ullrich RK: Radiation-induced activation of a common
variant of EGFR confers enhanced radioresistance. Radiother Oncol.
72:267–273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heimberger AB, Hlatky R, Suki D, Yang D,
Weinberg J, Gilbert M, Sawaya R and Aldape K: Prognostic effect of
epidermal growth factor receptor and EGFRvIII in glioblastoma
multiforme patients. Clin Cancer Res. 11:1462–1466. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JC, Vivanco I, Beroukhim R, Huang JHY,
Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, et
al: Epidermal growth factor receptor activation in glioblastoma
through novel missense mutations in the extracellular domain. PLoS
Med. 3:e4852006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Raizer JJ, Abrey LE, Lassman AB, Chang SM,
Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, et
al: North American Brain Tumor Consortium: A phase II trial of
erlotinib in patients with recurrent malignant gliomas and
nonprogressive glioblastoma multiforme postradiation therapy.
Neuro-oncol. 12:95–103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Libermann TA, Razon N, Bartal AD, Yarden
Y, Schlessinger J and Soreq H: Expression of epidermal growth
factor receptors in human brain tumors. Cancer Res. 44:753–760.
1984.PubMed/NCBI
|
|
25
|
Kawamoto T, Sato JD, Le A, Polikoff J,
Sato GH and Mendelsohn J: Growth stimulation of A431 cells by
epidermal growth factor: Identification of high-affinity receptors
for epidermal growth factor by an anti-receptor monoclonal
antibody. Proc Natl Acad Sci USA. 80:pp. 1337–1341. 1983;
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Waksal HW: Role of an anti-epidermal
growth factor receptor in treating cancer. Cancer Metastasis Rev.
18:427–436. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goldstein NI, Prewett M, Zuklys K,
Rockwell P and Mendelsohn J: Biological efficacy of a chimeric
antibody to the epidermal growth factor receptor in a human tumor
xenograft model. Clin Cancer Res. 1:1311–1318. 1995.PubMed/NCBI
|
|
28
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, et al: EPIC: Phase III trial of
cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin
Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pirker R, Pereira JR, Szczesna A, von
Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT,
Ganul V, et al: FLEX Study Team: Cetuximab plus chemotherapy in
patients with advanced non-small-cell lung cancer (FLEX): An
open-label randomised phase III trial. Lancet. 373:1525–1531. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eller JL, Longo SL, Kyle MM, Bassano D,
Hicklin DJ and Canute GW: Anti-epidermal growth factor receptor
monoclonal antibody cetuximab augments radiation effects in
glioblastoma multiforme in vitro and in vivoNeurosurgery. 56. pp.
155–162. discussion 162; 2005, View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patel D, Lahiji A, Patel S, Franklin M,
Jimenez X, Hicklin DJ and Kang X: Monoclonal antibody cetuximab
binds to and down-regulates constitutively activated epidermal
growth factor receptor vIII on the cell surface. Anticancer Res.
27(5A): 3355–3366. 2007.PubMed/NCBI
|
|
33
|
Stragliotto G, Vega F, Stasiecki P, Gropp
P, Poisson M and Delattre JY: Multiple infusions of anti-epidermal
growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in
patients with recurrent malignant gliomas. Eur J Cancer.
32A:636–640. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baselga J: Targeting tyrosine kinases in
cancer: The second wave. Science. 312:1175–1178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vivanco I, Robins HI, Rohle D, Campos C,
Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N,
et al: Differential sensitivity of glioma- versus lung
cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer
Discov. 2:458–471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baumann M, Krause M, Dikomey E, Dittmann
K, Dörr W, Kasten-Pisula U and Rodemann HP: EGFR-targeted
anti-cancer drugs in radiotherapy: Preclinical evaluation of
mechanisms. Radiother Oncol. 83:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rich JN and Bigner DD: Development of
novel targeted therapies in the treatment of malignant glioma. Nat
Rev Drug Discov. 3:430–446. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
van den Bent MJ, Brandes A, Rampling R,
Kouwenhoven M, Kros JM, Carpentier AF, Clement P, Klughammer B,
Gorlia T and Lacombe D: Randomized phase II trial of erlotinib (E)
versus temozolomide (TMZ) or BCNU in recurrent glioblastoma
multiforme (GBM): EORTC 26034. J Clin Oncol. 25:20072005.
|
|
39
|
Thiessen B, Stewart C, Tsao M, Kamel-Reid
S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P,
McIntosh L, et al: A phase I/II trial of GW572016 (lapatinib) in
recurrent glioblastoma multiforme: Clinical outcomes,
pharmacokinetics and molecular correlation. Cancer Chemother
Pharmacol. 65:353–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jorissen RN, Walker F, Pouliot N, Garrett
TPJ, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mizoguchi M, Betensky RA, Batchelor TT,
Bernay DC, Louis DN and Nutt CL: Activation of STAT3, MAPK, and AKT
in malignant astrocytic gliomas: Correlation with EGFR status,
tumor grade, and survival. J Neuropathol Exp Neurol. 65:1181–1188.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stover DR, Becker M, Liebetanz J and Lydon
NB: Src phosphorylation of the epidermal growth factor receptor at
novel sites mediates receptor interaction with Src and P85 alpha. J
Biol Chem. 270:15591–15597. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao TT, Le Francois BG, Goss G, Ding K,
Bradbury PA and Dimitroulakos J: Lovastatin inhibits EGFR
dimerization and AKT activation in squamous cell carcinoma cells:
Potential regulation by targeting rho proteins. Oncogene.
29:4682–4692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gallia GL, Rand V, Siu I-M, Eberhart CG,
James CD, Marie SKN, Oba-Shinjo SM, Carlotti CG, Caballero OL,
Simpson AJG, et al: PIK3CA gene mutations in pediatric and adult
glioblastoma multiforme. Mol Cancer Res. 4:709–714. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang H, Wang H, Zhang W, Huang HJ, Liao
WSL and Fuller GN: Analysis of the activation status of Akt,
NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest.
84:941–951. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wick W, Puduvalli VK, Chamberlain MC, van
den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S,
Musib L, et al: Phase III study of enzastaurin compared with
lomustine in the treatment of recurrent intracranial glioblastoma.
J Clin Oncol. 28:1168–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Batzer AG, Rotin D, Ureña JM, Skolnik EY
and Schlessinger J: Hierarchy of binding sites for Grb2 and Shc on
the epidermal growth factor receptor. Mol Cell Biol. 14:5192–5201.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pawson T: Protein modules and signalling
networks. Nature. 373:573–580. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Marshall CJ: Cell signalling. Raf gets it
together. Nature. 383:127–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
